Boston – July 11, 2014 – Cooley LLP announced today that it advised the underwriters on Minerva Neurosciences, Inc.'s $32.7 million IPO. Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company now trades on the NASDAQ Global Stock Market under the symbol "NERV."
Jefferies LLC acted as sole book-running manager for the offering and Baird and JMP Securities acted as co-managers.
The Cooley corporate securities team advising the underwriters included partners Nicole Brookshire, Darren DeStefano and Charlie Kim, and associates Veer Bhavnagri, Kristin VanderPas, Rebecca Jones, Chris Wheeler and Nancy Zhao. Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (regulatory); partner Bill Christiansen (intellectual property); partner Renee Deming and associate Sarah Dale (compensation and benefits); and partner Susan Cooper Philpot (tax).
Thus far in 2014, Cooley has advised on 65 completed public offerings, including 32 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.